University of Wisconsin–Madison Medical College of Wisconsin

Diagnosis of Chagas Disease by Detecting Species-Specific Repetitive Genomic DNA from Filtered Human Urine Samples

Miriam Price, BS; Nilanjan Lodh, PhD

WMJ. 2024;123(3):199-203.

Download full-text pdf

ABSTRACT

Introduction: Chagas disease caused by Trypanosoma cruzi (T cruzi) found in the Americas is often missed during the early stage of infection due to lack of sensitive diagnostic tests. The classic immunological and parasitological tests often fail in the acute phase due to the nonspecific and low antibody level nature of the infection and in the chronic phase due to low levels of trypanosomes in the blood. For successful control strategies, there must be a sensitive and specific diagnostic test.

Objective/Methods: We have demonstrated the possibility (proof of concept) of detecting T cruzi-specific repeat DNA via polymerase chain reaction (PCR) by (1) spiking 15 urine samples collected from volunteers free of prior infection with 3 different concentrations of T cruzi (3 strains), Trypanosoma brucei, and Trypanosoma rhodesiense (African strain) genomic DNA and (2) from filtered collected clinical samples from Argentina. Three sets of primers were used.

Results: Our approach detected repeat DNA specific for T cruzi strains from 1 clinical sample by 2 sets of primer and from spiked urine by all 3 sets of primer but not the African species. A serial dilution (spiking) also was performed on T cruzi strains to detect sensitivities of the assay. One set of primers constantly detected satellite DNA for all T cruzi strains from 70 pg/μl to 175 fg/μl.

Conclusions: We were able to demonstrate the feasibility of detecting T cruzi-specific DNA from filtered urine samples by sensitive and specific PCR assay. Besides the evident increased sensitivity and specificity of primers, our approach can be used to explore Chagas prevalence in endemic areas – especially in congenital Chagas newborn screening – and in the acute phase.


Author Affiliations: Marquette University College of Health Sciences, Milwaukee, Wisconsin (Price, Lodh).
Corresponding Author: Nilanjan Lodh, PhD, Department of Medical Laboratory Science, 560 N 16th St, Schroeder Complex 274, Milwaukee, WI 53201; phone 414.288.3404; email nilanjan.lodh@marquette.edu; ORCID ID 0000-0002-0363-3538
Acknowledgements: The authors wish to thank Professor Clive Shiff, PhD, Johns Hopkins School of Public Health, for sharing clinical samples used for this study. They also would like to acknowledge the volunteers who donated urine for this study. The genomic DNA from the following were obtained through BEI Resources, NIAID (full text), and the National Institutes of Health (NIH): Trypanosoma cruzi, Strain DM28c (TcI), NR-50236; Trypanosoma cruzi, Strain CL (TcVI), NR-50237; Trypanosoma cruzi, Strain G (TcI), NR-50238; Trypanosoma rhodesiense, Strain KETRI 243, NR-49828; and Trypanosoma brucei, Strain STIB 247, NR-49829.
Funding/Support: None declared.
Financial Disclosure: None declared.
Share WMJ